| 宜海杰 韩秀平 丁国平 姚翠娥 王莉.左西孟旦对急性心衰患者心功能及cTnT, hs-CRP, NT-proBNP水平影响[J].,2017,17(7):1314-1317 |
| 左西孟旦对急性心衰患者心功能及cTnT, hs-CRP, NT-proBNP水平影响 |
| Effect of Levosimendan on Cardiac Function and cTnT, hs-CRP andNT-proBNPLevels in Patients with Acute Heart Failure |
| |
| DOI： |
| 中文关键词: 急性心力衰竭 左西孟旦 cTnT hs-CRP NT-proBNP |
| 英文关键词: Acute heart failure Levosimendan cTnT hs-CRP NT-proBNP |
| 基金项目: |
|
| 摘要点击次数: 825 |
| 全文下载次数: 792 |
| 中文摘要: |
| 目的：观察左西孟旦对急性心力衰竭患者心功能及cTnT、hs-CRP、NT-proBNP水平影响。方法：选取在我院就诊的327 例急
性心力衰竭患者，按照治疗方式不同，分为观察组（常规治疗+ 左西孟旦）164 例和对照组（常规治疗）163 例，对比两组用药前及
用药后24 h 的左心射血分数（LVEF）、每搏输出量（SV）、肌钙蛋白T（cTnT）、超敏C 反应蛋白（hs-CRP）和氨基末端B 型利钠肽前
体（NT-proBNP）水平。结果：治疗前，两组LVEF和SV 比较，差异无统计学意义（P>0.05）。治疗后观察组LVEF 和SV 均显著高于
治疗前（P<0.05）；对照组LVEF显著高于治疗前（P<0.05），SV 与治疗前比较，差异无统计学意义（P>0.05）。治疗后观察组LVEF和
SV 均显著高于对照组（P<0.05）。治疗前两组cTnT、hs-CRP、NT-proBNP 水平比较，差异无统计学意义（P>0.05）。治疗后两组
cTnT、hs-CRP、NT-proBNP 水平均显著低于治疗前（P<0.05）。治疗后观察组cTnT、hs-CRP、NT-proBNP水平显著低于对照组（P<0.
05）。两组不良反应比较差异无统计学意义(P＞0.05)。结论：左西孟旦治疗急性心力衰竭可明显增加心肌收缩力，抑制心肌重塑，减
轻炎症反应，改善患者预后。 |
| 英文摘要: |
| Objective:To observe the effect of levosimendan on cardiac function and cTnT, hs-CRP and NT-proBNP levels in patients
with acute heart failure.Methods:327 cases of patients with acute heart failure in our hospital were selected in accordance with the
different treatment modalities, 163 patients in the control group were given routine treatment and 164 casesin the observation group were
given conventional treatment combined with levosimendan. The left heart shot ejection fraction (LVEF), stroke volume (SV), cardiac troponin
T (cTnT) and ultra sensitive C reactive protein (hs CRP) and N-terminal pro-B-type natriuretic peptide (NT proBNP) level were detected
before treatment and 24 h after treatment and compared between two groups.Results:There was no significant difference in LVEF
and SV before treatment between the two groups (P>0.05). After treatment, LVEF and SV level were significantly higher than before
treatment inthe observation group, (P<0.05); and the LVEF level in control group was significantly higher than before treatment (P<0.05),
but SV level was not statistically significant compared with before treatment (P>0.05). After treatment, the LVEF and SV level were significantly
higher observation group than that of control group (P<0.05). The difference in the level of cTnT, hs-CRP, NT-proBNPwas not
statistically significant before treatment (P>0.05), and after treatment, the levels of cTnT, hs-CRP and NT-proBNP were significantly
lower compared with before treatment (P<0.05), and they were significantly lower in the observation group than those of the control
group (P<0.05). No significant differences in the rate of adverse reactions between the two groups (P>0.05).Conclusion:Levosimendan
can significantly increase myocardial contractility, inhibit myocardial remodeling, reduce the inflammation and improve the prognosis of
pa- tients with acute heart failure. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
